Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis

Histology and Histopathology

Volumn 24, Issue 8, 2009, Pages 991-997

  Sampaio Almeida, Manuella S ^a   Vettore, André L ^a,b   Yamamoto, Mihoko ^a   de Lourdes Chauffaille, Maria L F ^a   Zago, Marco Antônio ^c   Colleoni, Gisele W B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Interleukin 6; International staging System; Multiple myeloma; Nuclear factor kappa B; Prognosis

Indexed keywords

DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NFKB1 PROTEIN, HUMAN; NFKBIA PROTEIN, HUMAN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; PILOT STUDY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; OSTEOPROTEGERIN; PILOT PROJECTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; VASCULAR CELL ADHESION MOLECULE-1;

EID: 69149093959     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., Dave S., Hurt E.M., Tan B., Zhao H., Stephens O., Santra M., Williams D.R., Dang L., Barlogie B., Shaughnessy J.D. Jr, Kuehl W.M. and Staudt L.M (2007). Frequent engagement of the classical and alternative NFkappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130.
2. Berenson J.R., Hongjin M.M. and Vescio R. (2001). The role of nuclear factor-kB in the biology and treatment of multiple myeloma. Semin. Oncol. 28, 626-633.
3. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj- Vadhan S., Estrov Z., Talpaz M. and Aggarwal B.B. (2004). Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103, 3175-3184.
4. Body J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., Holloway D., Peterson M.C. and Bekker P.J. (2006). A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12, 1221-1228.
5. Brocke-Heidrich K., Kretzschmar A.K., Pfeifer G., Henze C., Löffler D., Koczan D., Thiesen H-J., Burger R., Gramatzki M. and Horn F. (2004). Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 103, 242-251.
6. Chauhan D., Hideshima T., Mitsiades C., Richardson P. and Anderson K.C. (2005a). Proteasome inhibitor therapy in multiple myeloma. Mol. Cancer Ther. 4, 686-692.
7. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., Nicholson B., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A. and Anderson K.C. (2005b). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419.
8. Condomines M., Hose D., Raynaud P., Hundemer M., De Vos J., Baudard M., Moehler T., Pantesco V., Moos M., Schved J-F., Rossi J-F., Rème T., Goldschmidt H. and Klein B. (2007). Cancer/Testis genes in multiple myeloma: Expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178, 3307-3315.
9. Giuliani N., Rizzoli V. and Roodman G.D. (2006). Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108, 3992-3996.
10. Gonzalez-Paz N., Chng W.J., McClure R.F., Blood E., Oken M.M., Van Ness B., James C.D., Kurtin P.J., Henderson K., Ahmann G.J., Gertz M., Lacy M., Dispenzieri A., Greipp P.R. and Fonseca R. (2007). Tumor suppression p16 methylation in multiple myeloma: biological and clinical implications. Blood 109, 1228-1232.
11. Greipp P.R., San Miguel J., Durie B.G.M., Crowley J.J., Barlogie B., Bladé J., Boccadoro M., Child J.A., Harousseau J-L., Kyle R.A., Lahuerta J.J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I. and Westin J. (2005). International Staging System for multiple myeloma. J. Clin. Oncol. 23, 1-9.
12. Haaber J., Abildgaard N., Knudsen L.M., Dahl I.M., Lodahl M., Thomassen M., Kerndrup G.B. and Rasmussen T. (2007). Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br. J. Haematol. 140, 25-35.
13. Kyle R.A. and Rajkumar S.V. (2004). Multiple Myeloma. N. Engl. J.Med. 351, 1860-1873.
14. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N., Treon S.P. and Anderson K.C. (2002). Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 99, 4079-4086.
15. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Kung A.L., Davies F.E., Morgan G., Akiyama M., Shringarpure R., Munshi N.C., Richardson P.G., Hideshima T., Chauhan D., Gu X., Bailey C., Joseph M., Libermann T.A., Rosen N.S. and Anderson K.C. (2006). Antimyeloma activity of heat shock protein-90 inhibition. Blood 107, 1092-1100.
16. Rajkumar S.V., Richardson P.G., Hideshima T. and Anderson K.C. (2005). Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630-639.
17. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J-L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J.F., Bladé J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D. and Anderson K.C. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498.
18. Richardson P.G., Hideshima T., Mitsiades C. and Anderson K.C. (2007). The emerging role of novel therapies for the treatment of relapsed myeloma. J. Natl. Compr. Canc. Netw. 5, 149-162.
19. Roodman G.D. (2004). Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664.
20. Sezer O., Heider U., Zavrski I., Kühne C.A. and Hofbauer L.C. (2003). RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101, 2094-2098.
21. The International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749-757.
22. Willis T.G. and Dyer M.J.S. (2000).The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96, 808-822.